MX2020003473A - Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. - Google Patents

Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Info

Publication number
MX2020003473A
MX2020003473A MX2020003473A MX2020003473A MX2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A MX 2020003473 A MX2020003473 A MX 2020003473A
Authority
MX
Mexico
Prior art keywords
viral
treatment
inhibitor
bacterial infections
infection
Prior art date
Application number
MX2020003473A
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2020003473A publication Critical patent/MX2020003473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a PD-0184264 para uso en un método para la profilaxis y/o tratamiento de una coinfección que comprende una infección bacteriana y una infección por virus de influenza o solo una infección viral o bacteriana. También se proporcionan composiciones que comprenden estos inhibidores para uso en la profilaxis y/o tratamiento de una co-infección que comprende una infección bacteriana y una infección por virus de influenza o solo una infección bacteriana o viral.
MX2020003473A 2017-10-17 2018-10-17 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. MX2020003473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17
PCT/EP2018/078335 WO2019076947A1 (en) 2017-10-17 2018-10-17 NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MX2020003473A true MX2020003473A (es) 2020-10-01

Family

ID=60484427

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003473A MX2020003473A (es) 2017-10-17 2018-10-17 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
MX2022016066A MX2022016066A (es) 2017-10-17 2020-07-13 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016066A MX2022016066A (es) 2017-10-17 2020-07-13 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Country Status (21)

Country Link
US (1) US11903917B2 (es)
EP (2) EP3973960A1 (es)
JP (2) JP7227967B2 (es)
KR (1) KR20200072499A (es)
CN (2) CN118141795A (es)
AU (1) AU2018351475A1 (es)
BR (1) BR112020007442A2 (es)
CA (1) CA3078424A1 (es)
CY (1) CY1124507T1 (es)
DK (1) DK3697405T3 (es)
EA (1) EA202090693A1 (es)
ES (1) ES2883639T3 (es)
HR (1) HRP20211252T1 (es)
HU (1) HUE055738T2 (es)
LT (1) LT3697405T (es)
MX (2) MX2020003473A (es)
PL (1) PL3697405T3 (es)
PT (1) PT3697405T (es)
SI (1) SI3697405T1 (es)
WO (1) WO2019076947A1 (es)
ZA (1) ZA202002069B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370384A1 (en) 2019-08-27 2022-11-24 Atriva Therapeutics Gmbh Combinations of mek inhibitors with cap-dependent endonuclease inhibitors
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0104933A3 (en) 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
HUP0202623A3 (en) 1999-07-16 2003-03-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DE10300222A1 (de) 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
CN103221043B (zh) * 2010-08-05 2016-04-06 卡斯西部储备大学 用于治疗神经元连接发育障碍的erk抑制剂
EP2903649A1 (en) * 2012-10-08 2015-08-12 Westfälische Wilhelms-Universität Münster Mek inhibitors in the treatment of virus diseases
CN113398271A (zh) * 2014-05-16 2021-09-17 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略
KR20220079573A (ko) 2019-10-08 2022-06-13 아트리바 테라퓨틱스 게엠베하 한타바이러스 감염의 치료를 위한 mek 억제제
EP3912623A1 (en) 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
CN111479566B (zh) 2024-05-07
JP2020537659A (ja) 2020-12-24
ES2883639T3 (es) 2021-12-09
MX2022016066A (es) 2023-02-02
SI3697405T1 (sl) 2021-11-30
PL3697405T3 (pl) 2021-12-13
JP2023058631A (ja) 2023-04-25
EP3697405A1 (en) 2020-08-26
CY1124507T1 (el) 2022-07-22
HRP20211252T1 (hr) 2021-11-12
CN118141795A (zh) 2024-06-07
CN111479566A (zh) 2020-07-31
WO2019076947A1 (en) 2019-04-25
EA202090693A1 (ru) 2020-10-19
ZA202002069B (en) 2021-10-27
CA3078424A1 (en) 2019-04-25
EP3973960A1 (en) 2022-03-30
DK3697405T3 (da) 2021-08-23
LT3697405T (lt) 2021-10-25
HUE055738T2 (hu) 2021-12-28
PT3697405T (pt) 2021-08-27
AU2018351475A1 (en) 2020-04-30
JP7227967B2 (ja) 2023-02-22
US11903917B2 (en) 2024-02-20
EP3697405B1 (en) 2021-07-14
BR112020007442A2 (pt) 2020-10-27
KR20200072499A (ko) 2020-06-22
US20200289445A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
EP4233898A3 (en) Influenza mrna vaccines
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
PH12017500207A1 (en) Indoles for use in influenza virus infection
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
EP3996716A4 (en) COMPOUNDS FOR TREATMENT OF INFLUENCE VIRUS INFECTION
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
EA202091849A1 (ru) Тиазолидные соединения для лечения вирусных инфекций
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c